Health at a Glance: Europe 2010

image of Health at a Glance: Europe 2010
This special edition of Health at a Glance focuses on health issues across the 27 European Union member states, three European Free Trade Association countries (Iceland, Norway and Switzerland) and Turkey. It gives readers a better understanding of the factors that affect the health of populations and the performance of health systems in these countries.Its 42 indicators present comparable data covering a wide range of topics, including health status, risk factors,  health workforce and health expenditure.

Each indicator in the book is presented in a user-friendly format, consisting of charts illustrating variations across countries and over time, brief descriptive analyses highlighting the major findings conveyed by the data, and a methodological box on the definition of the indicators and any limitations in data comparability. An annex provides additional information on the demographic and economic context within which health systems operate.   

This publication is the result of collaboration between the OECD and the European Commission, with the help of national data correspondents from the 31 countries.



Screening, Survival and Mortality for Cervical Cancer

Cervical cancer is largely preventable. Screening by regular pelvic exam and pap smears can identify premalignant lesions, which can be effectively treated before the occurrence of the cancer. Regular screening also increases the probability of diagnosing early stages of the cancer and improving survival. Consequently, the Council of the European Union and the European Commission promote population based cancer screening programmes among member states (European Union, 2003; European Commission, 2008c) and European countries have instituted screening programmes with specific periodicity and target groups. In addition, promising cancer preventing vaccines have been developed based on the discovery that cervical cancer is caused by sexual transmission of certain forms of the Human Papilloma Virus. The efficacy and safety of those vaccines is now well established, but debates about cost-effectiveness and the implications of vaccination programmes for teenagers for a sexually transmitted disease continue in a number of countries (Huang, 2008).


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error